The Woman Who Keeps Asking What’s Next — and Building the Answer

There is a question that lives at the heart of every truly consequential career in science. Not “what do I know?” or even “what can I prove?” but something less comfortable, more restless, and ultimately more powerful: “What’s next?” For Samiksha Shah, that question has never been rhetorical. It has been the engine of everything she has built.

From the laboratories of Boston and Cambridge to the corridors of Biogen and Novartis and eventually to the founding of her own venture, What’s Next for Pharma, Samiksha’s career has been shaped not by the comfort of established paths but by the deliberate, sometimes uncomfortable, always purposeful act of stepping into the unknown first. She is a neuroscientist by training, a pharmaceutical strategist by experience, and a solo entrepreneur by choice—and it is that last distinction, perhaps more than any other, that has most profoundly shaped who she is as a leader.

Originally from Mumbai, she built her scientific foundation across three of the most demanding research institutions in the United States: Boston University, Brandeis University, and MIT. She graduated with high honors and a place on the Dean’s List. But what those years gave her was not simply a command of biochemistry and neuroscience. They gave her a framework for thinking about transformation at scale: how industries evolve, how systems break, and how the people willing to ask the right questions at the right moment end up building the things that matter.

Fifteen Years at the Intersection of Discovery and Business

There is a particular tension that anyone who has moved between scientific research and pharmaceutical commerce will recognize immediately. On one side sits the world of discovery, patient, methodical, and driven by curiosity and the long horizon of what might one day be possible. On the other sits the world of business: quarterly targets, pipeline pressures, regulatory timelines, and the relentless question of whether a molecule will ever make it to market.

Samiksha has spent fifteen years living inside that tension and has come to see it not as a contradiction to be managed but as a creative space to be occupied. Her career arc from early-stage life science startups to mid-sized biotechnology ventures to large pharmaceutical organizations, including Biogen and Novartis, was not a ladder climbed in a straight line. It was a deliberate education, built across the full spectrum of how the industry actually operates.

At Biogen, where she earned back-to-back Teaming and Leading Awards for Neuromuscular Research from 2018 through 2020, culminating in the Biogen Success Award in 2021, she was not simply contributing to research programs. She was learning what it looks like when scientific ambition meets institutional scale and developing the strategic fluency that would eventually make founding What’s Next for Pharma feel not like a leap, but like a logical next step.

On Technology, and the Leaders Who Will Ride the Wave

Few conversations in the pharmaceutical world generate as much noise right now as the question of what artificial intelligence and automation will do to the industry. The answers range from the utopian to the catastrophic, and most of them miss the point that Samiksha has been making consistently and, increasingly, loudly.

The transformation underway is not simply about efficiency. It is about a fundamental redesign of how therapeutics are conceived, developed, validated, and delivered. Digital discovery labs are selecting molecules based on best-fit and novelty-based approaches. Clinical trial design is being guided by biomarker intelligence. Manufacturing and compliance systems are being simulated through digital twin capabilities. The entire operating model of the industry, the workforce, the systems, and the decision-making architecture are being rebuilt from the inside out.

It is a distinction that sounds simple but is, in practice, one of the most difficult calls a pharmaceutical executive has to make right now. The pressure to automate is real. The temptation to confuse activity with progress is equally real. What Samiksha is describing is something harder: the discipline to ask, before every technology investment, whether it creates genuine value for patients, for pipelines, and for the people building them.

Fearlessness as a Core Leadership Value

Ask Samiksha to describe the values that guide her leadership, and she will not give you a corporate framework or a curated list of competencies. She will give you something more honest and ultimately more useful: a set of convictions forged through experience rather than articulated in advance.

That phrase “leaders who direct and guide values” deserves to sit with the reader for a moment. At a time when the pharmaceutical industry is arguably more technically capable than it has ever been, the limiting constraint is not knowledge. It is wisdom. The ability to look at an extraordinary array of tools and ask, with genuine ethical seriousness, which ones to use, when, and in whose service. Samiksha believes that is a leadership question, not a technical one.

The Most Humbling Leadership Experience

For all the professional milestones she has accumulated—the awards, the published research, the advisory council memberships, the recognition as one of India’s trailblazing entrepreneurs—Samiksha is disarmingly candid about where her most significant leadership education has actually taken place. Not inside a large organization with institutional support and established infrastructure. But in the day-to-day, sometimes isolating, ultimately clarifying reality of building a solo-founded venture from the ground up.

Solo entrepreneurship forces a particular kind of clarity on a leader. Without a management layer to filter feedback or a large team to absorb decisions, the gap between self-perception and reality closes very quickly. She has come to describe this as developing a profound awareness of one’s own capabilities and limitations—not as a source of doubt, but as the foundation for sharper, more honest decision-making.

Alongside that self-awareness, she has cultivated something equally important: the ability to hold self-assurance and intellectual humility at the same time. To walk into a room with an idea she believes in and present it with genuine confidence, while remaining open to being changed by what she hears. It is, she says, what consistently produces the most robust and enduring professional partnerships.

Innovation Is Not a Department

One of the most persistent misconceptions in the pharmaceutical industry is that innovation and rigor exist on opposite ends of a spectrum—that to move fast and think differently, something must be sacrificed: quality, perhaps, or compliance, or patient-centered design. Samiksha rejects this framing entirely, and not as a theoretical position but as a lived operational reality.

This is a position that cuts against a great deal of entrenched behavior in large pharmaceutical companies, where innovation is frequently siphoned into R&D and compliance is treated as a constraint on creativity rather than a design requirement built in from the start. What Samiksha is describing is a more integrated and ultimately more effective model: one where regulatory strategy is part of a therapy's design from the very beginning, where the patient’s experience is a specification rather than an afterthought, and where quality runs as a thread through every phase of development.

The Future Belongs to Custom Medicine

When Samiksha looks at the pharmaceutical landscape over the next decade, she sees a sector poised at the edge of something genuinely category-defining—a shift that moves well beyond the efficiency gains of automation and into something more fundamental: the personalization of medicine itself.

Genetic medicine, precision medicine, therapeutics designed to reach patient populations that have historically been underserved or entirely overlooked—these, she believes, will be the defining developments of the coming years. Paired with transparent systems that allow patients and clinicians to better understand what is actually happening inside the body in response to a therapy, the result will be medicines that do not simply treat conditions but are built around the individual experiencing them.

Underlying all of this, she argues, is the imperative of stronger cross-sector partnerships. Between pharmaceutical companies and healthcare providers. Between clinical teams and regulators. Between researchers and policymakers. Knowledge shared in real time, she believes, remains the most underutilized asset in the entire industry.

DE&I Is Not a Seminar. It Is a Measure of Innovation.

Among the many convictions She holds with genuine force, her view on diversity, equity, and inclusion is perhaps the most directly and usefully reframed.

Organizations that treat diversity as a compliance function—something to be reported, celebrated seasonally, and then filed away—will, she argues, find themselves consistently outpaced by organizations where diverse perspectives are genuinely integrated into how decisions are made, how problems are framed, and how solutions are built. The correlation between inclusion and innovation is not incidental. It is causal. And She does not make that argument from a position of abstraction. She makes it from the inside of her own career.

The Legacy of a Perpetual Question

The name Samiksha gave her venture, What’s Next for Pharma, is not accidental. It is, in the most precise sense, a mission statement. Not a declaration of what she has already achieved, but an ongoing commitment to the question that has always driven her forward. And when she describes the legacy she hopes to leave, that question sits at the very center of it.

For the pharmaceutical industry, that kind of restless, purposeful energy is not a luxury. It is a necessity. A structured and regulated industry, by its very nature, moves slowly and deliberately. The breakthroughs that matter—the ones that reach patients who had no options, that open treatment categories that did not exist before, and that make good on the industry’s fundamental promise—only happen when people like Samiksha Shah refuse to accept the current answer as the final one.

Fifteen years in. A neuroscience foundation forged at MIT and Brandeis. A body of peer-reviewed research. Multiple recognitions from Biogen. A seat on the Harvard Business Review Advisory Council. A venture she built alone, from the ground up. A growing community of pharmaceutical professionals gathered around one endlessly generative question.

What’s next? In Samiksha Shah’s hands, that question is not an ending. It is, and has always been, where every good story begins.